BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 7778571)

  • 1. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus.
    Escalante A; Brey RL; Mitchell BD; Dreiner U
    Am J Med; 1995 Jun; 98(6):559-65. PubMed ID: 7778571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
    Samarkos M; Davies KA; Gordon C; Loizou S
    Clin Rheumatol; 2006 Mar; 25(2):199-204. PubMed ID: 16091839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.
    Frodlund M; Vikerfors A; Grosso G; Skogh T; Wetterö J; Elvin K; Gunnarsson I; Kastbom A; Dahlström Ö; Rönnelid J; Svenungsson E; Sjöwall C
    Clin Exp Immunol; 2018 Oct; 194(1):27-38. PubMed ID: 30208508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis.
    Musial J; Swadzba J; Motyl A; Iwaniec T
    J Rheumatol; 2003 Apr; 30(4):723-30. PubMed ID: 12672190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity.
    Carmo-Pereira S; Bertolaccini ML; Escudero-Contreras A; Khamashta MA; Hughes GR
    Ann Rheum Dis; 2003 Jun; 62(6):540-3. PubMed ID: 12759291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus.
    Reshetnyak T; Cheldieva F; Cherkasova M; Lila A; Nasonov E
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?
    Uludağ Ö; Çinar S; McDonnell T; Çene E; Yalçinkaya Y; Gül A; Inanç M; Artim Esen B
    Turk J Med Sci; 2023; 53(5):1067-1074. PubMed ID: 38813003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of anticardiolipin antibody in patients with systemic lupus erythematosus and its association with clinical manifestations.
    Basiri Z; Gholyaf M; Faridnia M; Nadi E; Bairanvand M
    Acta Med Iran; 2013; 51(1):35-40. PubMed ID: 23456582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibodies to beta2-glycoprotein I and antibodies to cardiolipin in antiphospholipid syndrome: analysis of sensitivity and specificity].
    Aleksandrova EN; Novikov AA; Reshetniak TM; Kliukvina HG; Reshetniak DV; Nasonov EL
    Klin Med (Mosk); 2003; 81(9):25-31. PubMed ID: 14598587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases.
    Merkel PA; Chang Y; Pierangeli SS; Convery K; Harris EN; Polisson RP
    Am J Med; 1996 Dec; 101(6):576-83. PubMed ID: 9003103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards.
    Cucurull E; Espinoza LR; Mendez E; Molina JF; Molina J; Ordi-Ros J; Gharavi AE
    Lupus; 1999; 8(2):134-41. PubMed ID: 10192508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.
    Swadzba J; De Clerck LS; Stevens WJ; Bridts CH; van Cotthem KA; Musial J; Jankowski M; Szczeklik A
    J Rheumatol; 1997 Sep; 24(9):1710-5. PubMed ID: 9292792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association?
    Sahin M; Duzgun N; Tunc SE; Tutkak H
    Clin Rheumatol; 2007 Feb; 26(2):154-60. PubMed ID: 16598413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients.
    López-Soto A; Cervera R; Font J; Bové A; Reverter JC; Muñoz FJ; Miret C; Espinosa G; Ordinas A; Ingelmo M
    Clin Exp Rheumatol; 1997; 15(2):143-9. PubMed ID: 9196865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus.
    Lee SS; Cho ML; Joo YS; Kim WU; Hong YS; Min JK; Lee SH; Park SH; Cho CS; Kim HY
    J Rheumatol; 2001 Mar; 28(3):520-4. PubMed ID: 11296952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome.
    Fanopoulos D; Teodorescu MR; Varga J; Teodorescu M
    J Rheumatol; 1998 Apr; 25(4):675-80. PubMed ID: 9558168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
    Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
    Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study.
    Stojanovich L; Kontic M; Djokovic A; Marisavljevic D; Ilijevski N; Stanisavljevic N; Mikovic Z; Petkovic M; Kovcin V
    Clin Exp Rheumatol; 2013; 31(2):234-42. PubMed ID: 23306109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations.
    Tektonidou MG; Petrovas CA; Ioannidis JP; Vlachoyiannopoulos PG; Moutsopoulos HM
    Eur J Clin Invest; 2000 Jul; 30(7):646-52. PubMed ID: 10886305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.